Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice

Psychopharmacology

Volumn 181, Issue 2, 2005, Pages 260-269

  Balerio, Graciela N ^a   Aso, Ester ^a   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

funaltrexamine; Anxiety; Elevated plus maze; Mouse; Naltrindole; Nicotine; Nor binaltorphimine; Opioid system

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; NICOTINE; NORBINALTORPHIMINE; OPIATE RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; MAZE TEST; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG SYNERGISM; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; MAZE LEARNING; MECAMYLAMINE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 23744436908     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2238-y     Document Type: Article

References (59)

1. Balfour DJ (1982) The effects of nicotine on brain neurotransmitter systems. Pharmacol Ther 16:269-282
2. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 163:111-117
3. Berrendero F, Kieffer BL, Maldonado R (2002) Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22:10935-10940
4. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A, Maldonado R (2005) Nicotine-induced antinociception, rewarding effects and physical dependence are decreased in mice lacking the pre-proenkephalin gene. J Neurosci 25:1103-1112
5. Brazell MP, Mitchell SN, Gray JA (1991) Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study. Neuropharmacology 30:823-833
6. Bremner JD, Krystal JH, Southwick SM, Charney DS (1996) Noradrenergic mechanisms in stress and anxiety. I. Preclinical studies. Synapse 23:28-38
7. Brioni JD, O'Neill AB, Kim DJ, Decker MW (1993) Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 238:1-8
8. Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (1994) Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. Pharmacol Exp Ther 271:353-361
9. Cao W, Burkholder T, Wilkins L, Collins AC (1993) A genetic comparison of behavioral actions of ethanol and nicotine in the mirrored chamber. Pharmacol Biochem Behav 45:803-809
10. Cheeta S, Irvine EE, File SE (2000a) The dorsal raphe nucleus is involved in nicotine tolerance and withdrawal responses in the social interaction test. J Psychopharmacol 14:A75
11. Cheeta S, Kenny PJ, File SE (2000b) Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 24:1053-1067
12. Cheeta S, Irvine E, File SE (2001) Social isolation modifies nicotine's effects in animal tests of anxiety. Br J Pharmacol 132:1389-1395
13. Corrigall WA, Coen KM (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176
14. Costall B, Kelly ME, Naylor RJ, Onaivi ES (1989) The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 33:197-203
15. Dani JA (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49:166-174
16. Decker MW, Meyer MD (1999) Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem Pharmacol 58:917-923
17. Decker MW, Brioni JD, Bannon AW, Arneric SP (1995) Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 56:545-570
18. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M (1995) Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem 64:1878-1883
19. Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42
20. File SE (1992) Behavioural detection of anxiolytic action. In: Elliot JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. Wiley, London, pp 25-44
21. File SE, Kenny PJ, Ouagazzal AM (1998) Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav Neurosci 112:1423-1429
22. File SE, Cheeta S, Kenny PJ, Ouagazzal A-M (1999) Roles of the dorsal raphe nucleus, lateral septum and dorsal hippocampus in nicotine's effects on anxiety. Soc Neurosci Abstr 24:1981
23. File SE, Kenny PJ, Cheeta S (2000) The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66:65-72
24. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta-and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200
25. Fu Y, Matta SG, James TJ, Sharp BM (1998) Nicotine-induced norepinephrine release in the rat amygdala and hippocampus is mediated through brainstem nicotinic cholinergic receptors. J Pharmacol Exp Ther 284:1188-1196
26. Gilbert DG, Robinson JH, Chamberlin CL, Spielberger CD (1989) Effects of smoking/nicotine on anxiety, heart rate, and lateralization of EEG during a stressful movie. Psychophysiology 26:311-320
27. Gray JA, Mitchell SN, Joseph MH, Grogoryan G, Daws S, Hodges H (1994) Neurochemical mechanisms mediating the behavioural and cognitive effects of nicotine. Drug Dev Res 31:3-17
28. Guimaraes S, Carobrez PP, De Aguiar JC, Graeff FG (1991) Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103:91-94
29. Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20:78-84
30. Hildebrand BE, Panagis G, Svensson TH, Nomikos GG (1999) Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21:560-574
31. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR (1991) Nicotine-induced alteration in Tyr-Gly-Gly and Metenkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12:161-166
32. Jackson HC, Ripley TL, Nutt DJ (1989) Exploring delta-receptor function using the selective opioid antagonist naltrindole. Neuropharmacology 28:1427-1430
33. Jessa M, Nazar M, Plaznik A (1995) Anxiolytic-like action of intrahippocampally administered NMDA antagonists in rats. Pol J Pharmacol 47:81-84
34. Karras A, Kane JM (1980) Naloxone reduces cigarette smoking. Life Sci 27:1541-1545
35. Kenny PJ, Cheeta S, File SE (2000) Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1A and not by muscarinic M1 receptors. Neuropharmacology 39:300-307
36. König M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535-538
37. Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18:22-29
38. Mathieu-Kia AM, Kellogg SH, Butelman ER, Kreek MJ (2002) Nicotine addiction: insights from recent animal studies. Psychopharmacology 162:102-118
39. Newman MB, Manresa JJ, Sanberg PR, Shytle RD (2002) Anxiolytic effects of mecamylamine in two animal models of anxiety. Exp Clin Psychopharmacol 10:18-25
40. Okuda H, Shioda S, Nakai Y, Nakayama H, Okamoto M, Nakashima T (1993) The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat. Neurosci Lett 161:183-186
41. Olausson P, Akesson P, Engel JA, Soderpalm B (2001) Effects of 5-HT1A and 5-HT2 receptor agonists on the behavioral and neurochemical consequences of repeated nicotine treatment. Eur J Pharmacol 420:45-54
42. Onaka T, Palmer JR, Yagi K (1996) Norepinephrine depletion impairs neuroendocrine responses to fear but not novel environmental stimuli in the rat. Brain Res 713:261-268
43. Ouagazzal AM, Kenny PJ, File SE (1999a) Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 144:54-60
44. Ouagazzal AM, Kenny PJ, File SE (1999b) Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety. Eur J Neurosci 11:3957-3962
45. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
46. Pierzchala K, Houdi AA, Van Loon GR (1987) Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 8:1035-1043
47. Pomerleau OF (1986) Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol Bull 22:865-869
48. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J (1983) Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 81:61-67
49. Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146:185-186
50. Seth P, Cheeta S, Tucci S, File SE (2002) Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 71:795-805
51. Sharp BM, Matta SG (1993) Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization. Endocrinology 133:11-19
52. Thompson RC, Mansour A, Akil H, Watson SJ (1993) Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 11:903-913
53. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A (1992) Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem Res 17:265-271
54. Tsuda M, Suzuki T, Misawa M, Nagase H (1996) Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 307:7-14
55. Vale AL, Green S (1986) Effects of chlordiazepoxide, nicotine and d-amphetamine in the rat potentiated startle model of anxiety. Behav Pharmacol 7:138-143
56. Ward SJ, Portoghese PS, Takemori AE (1982) Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther 220:494-498
57. Ward SJ, Fries DS, Larson DL, Portoghese PS, Takemori AE (1985) Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA). Eur J Pharmacol 107:323-330
58. Watkins SS, Stinus L, Koob GF, Markou A (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292:1053-1064
59. Wewers ME, Dhatt R, Tejwani GA (1998) Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology 140:185-190